Related Articles
Cariprazine: New FDA Indication for MDD Augmentation
On Dec 16, 2022: AbbVie announced that FDA has approved Cariprazine as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in…
Lumateperone: Newest FDA Approved Medication for Bipolar Depression
Dec 20, 2021. We know that Lumateperone received its first FDA approval for the management of adult schizophrenia in 2019, but FDA has just approved…
Journal Club #2: Omega-3 Fatty Acids for MDD Treatment (ISNPR Practice Guidelines)
Today we posted the following second journal club in PEFA Journal Club’s discussion series: Journal Club #2: International Society for Nutritional Psychiatry Research Practice Guidelines…
Preferred Medication for Acute Bipolar Mania: Comparing Two Landmark Studies
Bipolar disorder is a complex psychiatric condition requiring effective management strategies, especially during acute manic episodes. Managing acute manic episodes requires a careful selection of…
Lumateperone Two New Dosages Approved: 21 mg & 10.5 mg
Lumateperone received its first FDA approval for the management of adult schizophrenia in 2019, and recently FDA has just approved this medication for depressive episodes…